Senores Pharmaceuticals FY26 Revenue Up 65.3% YoY

Senores Pharmaceuticals reported 65.3% YoY revenue growth to ₹401.7 Cr in FY26, driven by 90.6% growth in regulated markets.
The company completed acquisitions of Zoraya Pharmaceuticals and 75% of Apnar Pharmaceuticals to strengthen US market presence and manufacturing capabilities.
Senores established Amerisyn JV for US federal market access and maintains strong pipeline with 51 approved ANDAs and 27 in development.
Cash flow from operations improved significantly to ₹75 Cr in FY26, with emerging markets business becoming cash flow positive.